Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CIPLA.NS
BuyPremium GrowerCipla Limited · Healthcare · India · $11.8B · Avg Vol: $12M/d
68
StockRankGet insider-trade alerts
Q
70
V
33
M
59
P/E (TTM)
32.7x
ROE
11.3%
D/E
0.0x
Dividend %
1.0%
COMPANY DESCRIPTION
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 224.7B | 254.5B | 271.5B | 277.1B | 7.2% | 281.6B | 304.9B | 341.7B | 11.0% |
| EPS (INR) | 34.72 | 51.05 | 65.29 | 48.03 | 11.4% | 41.80 | 48.28 | 60.34 | 12.1% |
| Shares | 807.2M | 807.4M | 807.6M | 807.8M | +0.1% | 807.9M | — | — | — |
| Debt | 8.0B | 5.6B | 4.4B | 6.1B | -8.6% | 6.2B | — | — | — |
| Equity | 234.1B | 267.1B | 311.9B | 344.3B | 13.7% | — | — | — | — |
| Op CF | 32.4B | 41.3B | 50.0B | 39.4B | 6.8% | 39.5B | — | — | — |
| Inv CF | -23.9B | -29.9B | -36.9B | -23.3B | — | — | — | — | — |
| Fin CF | -9.6B | -12.0B | -12.9B | -12.3B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-7.5%
SMA 50SMA 200
Close
$14.28
RSI (14)
32.8
52W High
$17.37
From 52W High
0.8%
SCORE BREAKDOWN
Quality
70
ROIC
14.9%82.9
ROE
11.3%73.8
GP/Assets
41.8%79.9
Op. Margin
12.5%69.1
FCF/Assets
2.0%55.7
Piotroski
431.0
Int. Cover
50.0x89.2
D/E Ratio
0.02x80.7
Current Ratio
3.44x60.4
Value
33
P/E (TTM)
32.7x36.9
EV/EBITDA
19.8x34.9
P/FCF
130.3x13.3
P/B
3.2x43.7
P/S
3.9x49.0
Div Yield
1.0%27.9
Momentum
59
52W High %
82%70.9
RS 6M
7%71.8
SMA 50/200
1.04x65.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+52%56.2
Q Growth
-39%13.3
FUNDAMENTALS
Market Cap
$11.8B
P/E (Forward)
21.5x
Gross Margin
63.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CIPLA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CIPLA.NS | Cipla Limited(you) | $11.8B | 68 | Buy |
| ZYDUSLIFE.NS | Zydus Lifesciences Limited | $12.1B | 68 | Buy |
| MANKIND.NS | Mankind Pharma Limited | $10.1B | 69 | Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
| DRREDDY.NS | Dr. Reddy's Laboratories Limited | $10.1B | 50 | Hold |
| DIVISLAB.NS | Divi's Laboratories Limited | $26.8B | 73 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| TORNTPHARM.NS | Torrent Pharmaceuticals Limited | $19.9B | 52 | Hold |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%